These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 22723594)

  • 1. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
    Ke HZ; Richards WG; Li X; Ominsky MS
    Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
    Soen S
    Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone: An Experimental Study in Nonhuman Primates.
    Florio M; Kostenuik PJ; Stolina M; Asuncion FJ; Grisanti M; Ke HZ; Ominsky MS
    J Bone Joint Surg Am; 2023 Aug; 105(15):1145-1155. PubMed ID: 37159527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
    Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
    Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
    Feng G; Chang-Qing Z; Yi-Min C; Xiao-Lin L
    Int Immunopharmacol; 2015 Jan; 24(1):7-13. PubMed ID: 25479724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
    Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
    J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.
    McDonald MM; Morse A; Mikulec K; Peacock L; Yu N; Baldock PA; Birke O; Liu M; Ke HZ; Little DG
    J Orthop Res; 2012 Oct; 30(10):1541-8. PubMed ID: 22457198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
    Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
    J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal Model.
    Shah SA; Kormpakis I; Havlioglu N; Ominsky MS; Galatz LM; Thomopoulos S
    J Bone Joint Surg Am; 2017 May; 99(10):855-864. PubMed ID: 28509826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin and DKK1: new players in renal bone and vascular disease.
    Evenepoel P; D'Haese P; Brandenburg V
    Kidney Int; 2015 Aug; 88(2):235-40. PubMed ID: 26083653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1.
    Tsourdi E; Rijntjes E; Köhrle J; Hofbauer LC; Rauner M
    Endocrinology; 2015 Oct; 156(10):3517-27. PubMed ID: 26218891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.
    Morvan F; Boulukos K; Clément-Lacroix P; Roman Roman S; Suc-Royer I; Vayssière B; Ammann P; Martin P; Pinho S; Pognonec P; Mollat P; Niehrs C; Baron R; Rawadi G
    J Bone Miner Res; 2006 Jun; 21(6):934-45. PubMed ID: 16753024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
    Ominsky MS; Li C; Li X; Tan HL; Lee E; Barrero M; Asuncion FJ; Dwyer D; Han CY; Vlasseros F; Samadfam R; Jolette J; Smith SY; Stolina M; Lacey DL; Simonet WS; Paszty C; Li G; Ke HZ
    J Bone Miner Res; 2011 May; 26(5):1012-21. PubMed ID: 21542004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.